Project Grant R15HL181635
Award Date 7/15/26
Completion Date 3/31/29
Dollars Obligated $586K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30341, USA
Similar Awards
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Thomas Jefferson University a $2.46 million Project Grant on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a collaborative, multi-project program investigating "Exploiting Emerging Ideas in G Protein-Coupled Receptor Biology and Pharmacology to Treat Asthma." The program, which extends through July 31, 2030, assembles a team of experts in G...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Missouri System $461,115 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research assessing dissolved phase 129-Xenon (129Xe) as a biomarker for gas-exchange and vascular function in asthma patients. The project, extending through June 30, 2029, will utilize hyperpolarized 129Xe magnetic resonance imaging (MRI) technology to non-invasively...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $233,250 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for August 31, 2028. This pilot research initiative will develop and evaluate anakinra, an interleukin-1 receptor antagonist (IL-1RA) currently approved for rheumatoid arthritis treatment, as a...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Utah a Project Grant totaling $740,709 under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with completion targeted for May 31, 2029. This research initiative focuses on defining cellular and molecular mechanisms by which early-life viral-induced inflammation drives asthma susceptibility through the reprogramming of type 2 innate lymphoid cells...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Illinois at Chicago a $2.39 million Project Grant on September 23, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research through May 31, 2029. The project, titled "Mechanistic Insights into Endotoxin-Induced Protection Against Allergenic Asthma and Its Therapeutic Potential," will deliver fundamental research outputs advancing...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded Massachusetts General Hospital a Project Grant of $1,579,554 on September 10, 2025, for research concluding June 30, 2030. The award funds an integrated genomic and functional research initiative to decipher the mechanisms underlying chronic obstructive pulmonary disease (COPD) and asthma—two of the most common and costly chronic respiratory...
- Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Washington University a Project Grant of $1.9M (awarded June 15, 2026; completion February 28, 2028) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct fundamental mechanistic research addressing chronic muco-obstructive lung disease. The research identifies and corrects a pathological reprogramming pathway in basal epithelial stem cells (basal-ESCs) that drives persistent airway...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $731,130 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 19, 2025, with completion scheduled for June 30, 2030. The award supports a multi-site, two-stage Sequential, Multiple Assignment, Randomized Trial (SMART) evaluating the effectiveness of a stepped-care mobile health intervention called ASTHMA...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Harvard Pilgrim Health Care, Inc. a $1.51 million Project Grant (CFDA 93.837: Cardiovascular Diseases Research) on September 25, 2025, to identify causal mechanisms of metabolites in family-based association studies of childhood asthma. The research leverages the Genetic Epidemiology of Asthma in Costa Rica Study (GACRS) cohort and the Childhood Asthma Management Program (CAMP) to examine the relationship...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Oklahoma Health Sciences Center a $2.08 million Project Grant (CFDA 93.837, Cardiovascular Diseases Research) effective September 25, 2025, through July 31, 2027, to conduct mechanistic research on estrogen signaling in chronic asthma. The research project will investigate how estrogen-metabolizing enzymes, particularly cytochrome P450 3A4 (CYP3A4) and its metabolite 16α-hydroxyestradiol...